Dynavax Technologies Corporation (DVAX)vsUnited Therapeutics Corporation (UTHR)
DVAX
Dynavax Technologies Corporation
$15.50
0.00%
HEALTHCARE · Cap: $1.82B
UTHR
United Therapeutics Corporation
$541.60
+1.84%
HEALTHCARE · Cap: $23.74B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 863% more annual revenue ($3.18B vs $330.51M). UTHR leads profitability with a 41.9% profit margin vs -13.1%. UTHR earns a higher WallStSmart Score of 67/100 (B-).
DVAX
Hold45
out of 100
Grade: D+
UTHR
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DVAX.
Margin of Safety
+62.9%
Fair Value
$1282.02
Current Price
$541.60
$740.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 69.3% YoY
Strong operational efficiency at 24.8%
17.7% revenue growth
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 45.0%
Safe zone — low bankruptcy risk
Earnings expanding 24.5% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of -7.1% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : DVAX
The strongest argument for DVAX centers on EPS Growth, Operating Margin, Revenue Growth. Revenue growth of 17.7% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.
Bear Case : DVAX
The primary concerns for DVAX are Market Cap, Return on Equity, Altman Z-Score.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio.
Key Dynamics to Monitor
DVAX profiles as a growth stock while UTHR is a mature play — different risk/reward profiles.
DVAX carries more volatility with a beta of 0.93 — expect wider price swings.
DVAX is growing revenue faster at 17.7% — sustainability is the question.
UTHR generates stronger free cash flow (173M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (67/100 vs 45/100), backed by strong 41.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dynavax Technologies Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company is headquartered in Emeryville, California.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?